An observational study in Covid19, sponsored by Koc University Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Koc University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in COVID-19 with a site in Turkey — 9 open to participants now, 11 under way, 3 of them phase 3. COVID-19 · Turkey.
Among the 429 studies in COVID-19 with a site in Turkey, this one is the 231st largest by enrollment of the 251 observational ones that give a count, is one of 167 that started in 2020, is one of 251 observational ones, and was the 86th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →9 of the 429 studies in COVID-19 with a site in Turkey are open now. Recruiting first, the newest first:
Pfizer · Sites in Turkey, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Turkey, United States, Argentina and 16 more countries
Ages 12+
Istanbul Medipol University Hospital · Sites in Turkey
Ages 18–50 · Healthy volunteers
AstraZeneca · Sites in Turkey, United States, Argentina and 36 more countries
Ages 18+
Gazi University · Sites in Turkey
Ages 18–75
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 26 · Phase 3 27 · Phase 4 4
First in 2018; this study’s year is marked. 167 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 64 across the 178 interventional studies, 148 across the 251 observational. Of the 342 that completed or were terminated, 19 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 429 have an industry lead sponsor. The 10 most frequent:
Koc University Hospital is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Koc University Hospital has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in Turkey that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 429 studies in COVID-19 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe multiorgan disease requiring hospitalization. The medium and long-term impact in survivors of COVID-19 on lung function, imaging by thoracic CT, exercise capacity, and health-related quality of life and the relation of these parameters remains to be determined.
Aim: To evaluate medium to late (visit 1: 6-12 months after hospital discharge) effects of COVID-19 on lung function, exercise capacity, thoracic CT findings, symptoms and HRQoL in patients with confirmed diagnosis of SARS-CoV-2 infection and the relation between these parameters.
Material and methods: Prospective cohort of subjects with laboratory and/or thoracic CT confirmed COVID-19 who were treated as inpatients. Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT) and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
The minimum sample size was estimated as 37 participants.
Adults with Covid-19 diagnosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
Diagnostic Test: spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire
Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
Forced vital capacity (FVC)
in ml
Time frame: at 6-12 months after discharge
Lung diffusion capacity for carbon monoxide (DLCO)
DLCO (%predicted); DLCO/alveolar volume- DLCO/VA (%predicted)
Time frame: at 6-12 months after discharge
6-minute walk test distance
m
Time frame: at 6-12 months after discharge
Short-form 36 questionnaire (SF-36)
scores range between 0 and 100 with higher scores indicating a better HRQoL
Time frame: at 6-12 months after discharge
Oxygen uptake at peak exercise
from incremental Cardiopulmonary exercise test (% of predicted)
Time frame: at 6-12 months after discharge
Minute-ventilation/carbon dioxide output during exercise
from incremental Cardiopulmonary exercise test (L/L)
Time frame: at 6-12 months after discharge
Dyspnea during exercise
from incremental Cardiopulmonary exercise test (measured with 10-point categorical Borg scale
Time frame: at 6-12 months after discharge
Thoracic CT findings
lung parenchymal abnormalities as percentage of occupied lung
Time frame: in the first week of pneumonia and at 6-12 months after discharge
Forced expiratory volume in 1 second
in ml and %predicted
Time frame: at 6-12 months after discharge
FEV1/FVC ratio
in %
Time frame: at 6-12 months after discharge
Forced vital capacity %predicted (FVC%)
in %
Time frame: at 6-12 months after discharge
Signs and symptoms
Recorded separately as present or absent) mortality (recorded as present or absent)
Time frame: in the first week of pneumonia and at 6-12 months after discharge
Time to hospital discharge
in days
Time frame: in hospital
ICU discharge
in days
Time frame: in hospital
Weaning from intubation
in days
Time frame: in the period of intensive care
Weaning from supplemental oxygen
in days
Time frame: in hospital
Weaning from noninvasive mechanical ventilation
in days
Time frame: in hospital
Mortality
recorded as present or absent
Time frame: in hospital and at 6-12 months after discharge
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Feb 2022, 16 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 16 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Koc University Hospital